Current status of bortezomib in the treatment of multiple myeloma

Current Hematologic Malignancy Reports

Volumn 2, Issue 2, 2007, Pages 128-137

  Cavo, Michele ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; LENALIDOMIDE; MELPHALAN; PREDNISONE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; VINCRISTINE;

ADVANCED CANCER; ANOREXIA; APOPTOSIS; BLOOD TOXICITY; BONE MARROW TOXICITY; CANCER CELL CULTURE; CANCER RELAPSE; CELL PROLIFERATION; CHROMOSOME 13; CHROMOSOME ABERRATION; CLINICAL TRIAL; DIARRHEA; DNA DAMAGE; DRUG DOSE ESCALATION; DRUG INHIBITION; DRUG MEGADOSE; DRUG WITHDRAWAL; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY FAILURE; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELOMA CELL; NEUROPATHIC PAIN; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; REVIEW; SALVAGE THERAPY; SENSORY NEUROPATHY; STROMA CELL; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BORONIC ACIDS; CELL LINE, TUMOR; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; CYTOKINES; DRUG SCREENING ASSAYS, ANTITUMOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KIDNEY FAILURE, CHRONIC; MULTICENTER STUDIES AS TOPIC; MULTIPLE MYELOMA; NEOPLASM PROTEINS; NF-KAPPA B; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; PYRAZINES; SALVAGE THERAPY; STEM CELL TRANSPLANTATION; STROMAL CELLS; TRANSPLANTATION, AUTOLOGOUS;

EID: 34248398487     PISSN: 15588211     EISSN: 1558822X     Source Type: Journal    
DOI: 10.1007/s11899-007-0018-y     Document Type: Review

References (50)

1. Ciechanover A, Orian A, Schwartz AL: Ubiquitin-mediated proteolysis: biological regulation via destruction. Bioessays 2000, 22:442-451.
2. Zwickl P, Voges D, Baumeister W: The proteasome: a macromolecular assembly designed for controlled proteolysis [review]. Philos Trans R Soc Lond B Biol Sci 1999, 354:1501-1511.
3. Kisselev AF, Goldberg AL: Proteasome inhibitors: from research tools to drug candidates. Chem Biol 2001, 8:739-758.
4. Voorhees PM, Dees EC, O'Neil B, Orlowski RZ: The proteasome as a target for cancer therapy. Clin Cancer Res 2003, 9:6316-6325.
5. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T: The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell 1994, 78:773-785.
6. Adams J, Palombella VJ, Sausville EA, et al.: Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res 1999, 59:2615-2622.
7. Cavo M: Proteasome inhibitor bortezomib for the treatment of multiple myeloma. Leukemia 2006, 20:1341-1352.
8. Hideshima T, Richardson P, Chauhan D, et al.: The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res 2001, 61:3071-3076.
9. Mitsiades CS, Richardson PG, Poulaki V, et al.: The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: therapeutic applications. Blood 2003, 101:2377-2380.
10. Ma MH, Yang HH, Parker K, et al.: The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res 2003, 9:1136-1144.
11. Orlowski RZ, Stinchcombe TE, Mitchell BS, et al.: Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies. J Clin Oncol 2002, 20:4420-4427.
12. Richardson PG, Barlogie B, Berenson J, et al.: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med 2003, 348:2609-2617.
13. Richardson PG, Barlogie B, Berenson J, et al.: Extended follow-up of a phase II trial in relapsed, refractory multiple myeloma: final time to event results from the SUMMIT trial. Cancer 2006, 106:1316-1319.
14. Jagannath S, Barlogie B, Berenson J, et al.: A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma. Br J Haematol 2004, 127:165-172.
15. • Richardson PG, Sonneveld P, Schuster MW, et al.: Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005, 352:2487-2498. In a prospective comparison of bortezomib with dexamethasone as salvage therapy for relapsed multiple myeloma, the superiority of bortezomib in terms of time to progression, response rate, and overall survival was demonstrated.
16. Bladé J, Samson D, Reece D, et al.: Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998, 102:1115-1123.
17. Richardson PG, Sonneveld P, Schuster M, et al.: Bortezomib continues demonstrates [sic] superior efficacy compared with high-dose dexamethasone in relapsed multiple myeloma: updated results of the APEX trail [sic] [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 2547.
18. Sonneveld P, Richardson PG, Schuster MW, et al.: Bortezomib at first relapse is superior to high-dose dexamethasone and more effective than when given later in relapsed multiple myeloma [abstract]. Haematologica 2005, 90(suppl 1):150: Abstract PO721.
19. Richardson PG, Barlogie B, Berenson J, et al.: Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood 2005, 106:2977-2981.
20. Jagannath S, Richardson PG, Sonneveld P, et al.: Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials. Leukemia 2007, 21:151-157.
21. Sagaster V, Ludwig H, Kaufmann H, et al.: Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia 2007, 21:164-168.
22. Berenson JR, Jagannath S, Barlogie B, et al.: Safety of prolonged therapy with bortezomib in relapsed or refractory multiple myeloma. Cancer 2005, 104:2141-2148.
23. Jagannath S, Barlogie B, Berenson JR, et al.: Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function. Cancer 2005, 103:1195-1200.
24. Chanan-Khan A, Kaufman JL, Mehta J, et al.: Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: a multicenter retrospective study [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:716a.
25. Lonial S, Waller EK, Richardson PG, et al.: Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma. Blood 2005, 106:3777-3784.
26. Richardson PG, Briemberg H, Jagannath S, et al.: Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib. J Clin Oncol 2006, 24:3113-3120.
27. Jagannath S, Richardson PG, Barlogie B, et al.: Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib alone. Haematologica 2006, 91:929-934.
28. Berenson JR, Yang HH, Swift R, et al.: Bortezomib in combination with melphalan in the treatment of relapse or refractory multiple myeloma: a phase I/II study [abstract]. Haematologica 2005, 90(suppl 1):150. Abstract PO728.
29. Popat R, Oakervee HE, Foot N, et al.: A phase I/II study of bortezomib and low dose intravenous melphalan (BM) for relapsed multiple myeloma [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:718a. Abstract 2555.
30. Palumbo A, Ambrosini MT, Pregno P, et al.: Velcade plus melphalan, prednisone, and thalidomide (V-MPT) for advanced multiple myeloma [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:717a. Abstract 2553.
31. Kropff M, Bisping G, Liebisch P, et al.: Bortezomib in combination with high-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:716a. Abstract 2549.
32. Zangari M, Barlogie B, Burns MJ, et al.: Velcade (V)-thalidomide (T)-dexamethasone (D) for advanced and refractory multiple myeloma (MM): long-term follow-up of phase I-II trial UARK 2001-37: superior outcome in patients with normal cytogenetics and no prior T [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:717a. Abstract 2552.
33. Mitsiades N, Mitsiades CS, Poulaki V, et al.: Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications. Blood 2002, 99:4525-4530.
34. Richardson P, Schlossman R, Munshi N, et al.: A phase 1 trial of lenalidomide (REVLIMID) with bortezomib (VELCADE) in relapsed and refractory multiple myeloma [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:110a. Abstract 365.
35. Hollmig K, Stover J, Talamo G, et al.: Addition of bortezomib (Velcade) to high dose melphalan (vel-mel) as an effective conditioning regimen with autologous stem cell support in multiple myeloma (MM) [abstract]. Blood (ASH Annual Meeting Abstracts) 2004, 104:266a. Abstract 929.
36. Giralt S, Aleman A, Lei X, et al.: Results of bortezomib (BTZ) therapy for myeloma (MM) patients relapsing after an allogeneic transplant. Preliminary results show efficacy without induction of GVHD [abstract]. Blood (ASH Annual Meeting Abstracts) 2004, 104:459a. Abstract 1651.
37. Anderson K, Richardson P, Chanan-Khan A, et al.: Single-agent bortezomib in previously untreated multiple myeloma (MM): results of a phase II multicenter study [abstract]. J Clin Oncol 2006, 24(18S): Abstract 7504.
38. Jagannath S, Durie B, Wolf J, et al.: Bortezomib therapy alone and in combination with dexamethasone for patients with previously untreated multiple myeloma. Blood (ASH Annual Meeting Abstracts) 2005, 106:231a. Abstract 783.
39. Harousseau JL, Attal M, Leleu X, et al.: Bortezomib plus dexamethasone as induction treatment prior to autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of an IFM phase II study. Haematologica 2006, 91:1498-1505.
40. • Oakervee HE, Popat R, Curry N, et al.: PAD combination therapy (PS-341/bortezomib, doxorubicin and dexamethasone) for previously untreated patients with multiple myeloma. Br J Haematol 2005, 129:755-762. Front-line therapy with bortezomib in combination with doxorubicin and dexamethasone in preparation for subsequent autologous transplantation yielded complete or near-complete response rate in the 30% range, which increased to more than 55% following a single autologous transplantation.
41. Popat R, Oakervee HE, Curry N, et al.: Reduced dose PAD combination therapy (PS-341/bortezomib, Adriamycin and dexamethasone) for previously untreated patients with multiple myeloma [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:717a. Abstract 2554.
42. Wang M, Delasalle K, Giralt S, Alexanian R: Rapid control of previously untreated multiple myeloma with bortezomibthalidomide-dexamethasone followed by early intensive therapy [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:231a. Abstract 784.
43. Barlogie B, Tricot G, Rasmussen E, ct al.: Total Therapy 3 (TT3) incorporating Velcade (V) intro upfront management of multiple myeloma (MM): comparison with TT2 + thalidomide (T) [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:337a. Abstract 1154.
44. • Mateos MV, Hernandez JM, Hernandez MT, et al.: Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 2006, 108:2165-2172. In elderly myeloma patients who arc not candidates for autologous transplantation, addition of bortezomib to standard melphalan-prednisone effected an impressive overall response rate in the 90% range, including 43% of complete or near-complete response.
45. Cavo M, Zamagni E, Tosi P, et al.: Superiority of thalidomide and dexamethasone over vincristine-doxorubicin-dexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma. Blood 2005, 106:35-39.
46. Rajkumar SV, Blood E, Vesole D, et al.: Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006, 24:431-436.
47. Rajkumar SV, Hayman SR, Lacy MQ, et al.: Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood 2005, 106:4050-4053.
48. Orlowski RZ, Voorhees PM, Garcia RA, et al.: Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies. Blood 2005, 105:3058-3065.
49. Chanan-Khan A, Miller KC, McCarthy P: A phase II study of Velcade (V), Doxil (D) in combination with low-dose thalidomide (T) as salvage therapy for patients with relapsed or refractory multiple myeloma (MM) and Waldenstrom's macroglobulinemia: encouraging preliminary results [abstract]. Blood (ASH Annual Meeting Abstracts) 2004, 104:665a. Abstract 2421.
50. Peles S, Fisher NM, Devine SM, et al.: Bortezomib (Velcade) when given pretransplant and once weekly as consolidation therapy following high dose chemotherapy (HDCT) leads to high rates of reactivation of varicella zoster virus (VZV) [abstract]. Blood (ASH Annual Meeting Abstracts) 2005, 106:Abstract 3237.